Similarly, olaparib also demonstrated a PFS benefit compared to chemotherapy (median PFS of 7 months for olaparib vs. 4.2 months for chemotherapy) in patients with gBRCAm and metastatic HER2‐negative breast cancer [8]. This evidence concerns the gene ERBB2 and breast carcinoma.